Download Free Medical Personalized Breast Cancer Care PowerPoint Presentation

Personalized Breast Cancer Care PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Familial Pancreatic Cancer, which is titled "Personalized Breast Cancer Care", to know about genetic/familial high risk assessment in breast cancer and role of specific markers on breast tissue in decision making of treatment.

Tags : Familial Pancreatic Cancer, Breast Cancer Care, genetic, familial high risk assessment, breast tissue, treatment

Published on : May 18, 2021 | Views : 1414 | Downloads : 7

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Personalized Breast Cancer Care Sunil Patel, MD Medical Oncology and Hematology Collom and Carney Clinic.
Slide 2-

No financial disclosure
Slide 3-

Personalized Breast Cancer Care Topics Role of genetic/familial high risk assessment Role of specific markers on breast tissue in decision making of treatment. For some patients, more(=chemo) is not better. - Role of genetic profiling of the tumor in decision making.
Slide 4-

Breast Cancer Progress Report Breast Cancer mortality rates have decreased by 2.3% annually since 1990 Source: Breast Cancer Facts and Figures 2005-2006 National Center for Health Statistics data as analyzed by NCI The decline in mortality is primarily due to early detection and new treatment methods
Slide 5-

The Stages of Breast Cancer Breast Cancer is diagnosed according to stages (stages 0 through IV) under the TNM classification. Factors used in staging of Breast Cancer: Tumor Size Size of primary tumor Nodal status Indicates presence or absence of cancer cells in lymph nodes Metastasis Indicates if cancer cells have spread from the affected breast to other areas of the body (i.e. skin, liver, lungs, bone) Source: National Cancer Institute
Slide 6-

Genetics Help us Identify Patients at High Risk of Developing Breast Cancer Genetics Genetics is the study of heredity While genetics influence genomics, genetics is responsible for only 5-10% of breast cancer Genetics focuses primarily on the likelihood of developing cancer Genetic tests find mutations, not disease Source: Understanding Cancer Series: Gene Testing, National Cancer Institute
Slide 7-

Genomics Help us Look at the Patients Individual Tumor Biology Genomics Genomics is the study of how genes interact and are expressed as a whole Genomics and gene expression profiling tools focus on the cancer itself and can help determine How aggressive is the cancer (prognosis) What is the likely benefit from treatment (prediction)
Slide 8-

Examples of Genetic and Genomic Tests Genetic Test BRCA1 and BRCA2 The genetic make up of patients is tested for BRCA1 and BRCA2 mutations. Patients with those mutations have higher chances of developing breast cancer. Genomic Test Oncotype DX® Breast Cancer Assay The expression level of 21 genes is measured in tumor tissue from patients that have already been diagnosed with breast cancer. This assay evaluates if a patient is going to recur (prognostic) and predicts benefit from chemotherapy and hormonal therapy (predictive) Mammaprint assay
Slide 9-

Genetic Risk Factor Assessment NX 42 year old white female with no family history of breast cancer, now has 4 cm right breast cancer. Biopsy confirmed IDC,ER+, HER2/neu + What’s next? – Surgery- ipsilateral or bilateral mastectomy, chemo, hormonal therapy? Or more?
Slide 10-

Breast & Ovarian Cancer Risk Assessment – for patients Age 50 y or younger Triple negative breast cancer ( ER-PR-Her2/Neu-) Two breast cancer primaries Breast cancer at any age - 1 or more close relative with breast or ovarian cancer at age 50 or younger -2 or more close relatives with breast and/or pancreatic cancer -women of Ashkenazi Jewish descent at any age breast/ovarian cancer. Other cancer history – Thyroid, sarcoma, adrenal , endometrial, pancreatic, brain cancer Ovarian cancer Male breast cancer.
Slide 11-

Patient NX NX 42 year old white female with no family history of breast cancer, now has 4 cm right breast cancer. Biopsy confirmed IDC,ER+, HER2/neu + What’s next? – Surgery- ipsilateral or bilateral mastectomy, chemo, hormonal therapy? Or more?
Slide 12-

Patient NX Should go I go for surgery first? Then chemo? Blood for BRCA 1 and 2 mutation.
Slide 13-

Patient MB MB is a 53 year old white male with right sided breast cancer, stage I.
Slide 14-

BReastCAncer Genes
Slide 15-

BReast CAncer Women have about a 1 in 7 chance of getting breast cancer in their lifetime. Most cancer is sporadic, about 5-10% of cases are genetically linked Women inheriting mutation of BRCA gene have increased chance of disease Also can lead to ovarian cancer
Slide 16-

The Numbers
Slide 17-

BRCA Genes BRCA 1 and BRCA 2 Roles they play
Slide 18-

Life is all about the right balance.
Slide 19-

What are they? BRCA 1 and BRCA 2 Known as breast and ovarian cancer susceptibility genes Tumor suppressor genes regulate the cycle of cell division by keeping cells from growing and dividing too rapidly or in an uncontrolled way inhibit the growth of cells that line the milk ducts in the breast Involved in many other functions including control of DNA replication and damage repair
Slide 20-

BRCA 1 Cloned in 1994 (Miki et al) Mapped to chromosome 17q21 5,592kb long 24 exons
Slide 21-

BRCA 2 Cloned in 1995 (Wooster et al.) Mapped to chromosome 13q12-13 10,254 kb (3,418 aa) 27 exons
Slide 22-

More Numbers
Slide 23-

Patient NX BRCA 1 mutation positive Neo-adjuvant chemotherapy then bilateral skin sparing mastectomy. Hormonal therapy Prophylactic bilateral salpingo-oopherectomy Genetic counseling for family members.
Slide 24-

Patient MB BRCA 2 mutation positive Chemotherapy Contra-lateral mastectomy PSA screening test.
Slide 25-

Topics Role of genetic/familial high risk assessment Role of specific markers on breast tissue in decision making of treatment. For some patients, more is not better. - Role of genetic profiling of the tumor in decision making.
Slide 26-

How Do We Assess Risk in Breast Cancer Patients? Classic Pathological Criteria Age Tumor Size Lymph Node Status ER/PR HER2 Tumor Grade AdjuvantOnline! Computer-based model
Slide 27-

ER/PR/Her2-Neu Estrogen receptor Progesterone receptor Her2/Neu – Human epidermal growth factor Receptor 2 ER/PR+ Her2/Neu – ER/PR – Her2/Neu – (Triple negative) ER/PR – Her2/Neu + ER/PR+ Her2/Neu +
Slide 28-

Triple-Positive Breast Cancer Triple-Negative Breast Cancer H&E ER-Neg PR-Neg HER2/neu-Neg ER-Pos PR-Pos HER2/neu-Pos H&E
Slide 29-

Treatment options Chemotherapy Endocrine therapy – Tamoxifen or Aromatase inhibitor - Anastrozole (Arimidex) , Letrozole (Femara) , Exemestane (Aromasin) Trastuzumab (Herceptin)
Slide 30-

HerceptinTM(trastuzumab)
Slide 31-

Triple negative breast cancer Hormone Receptor - /HER2 - Chemotherapy for tumor more than 0.5 cm. Nodal involvement.
Slide 32-

Hormone Receptor Positive, HER2 Positive Breast Cancer 0.5 cm or less tumor size – Adjuvant endocrine therapy 0.6 to 1 cm – Adjuvant endocrine +/- chemo with trastuzumab. > 1 cm tumor size and/or lymph node involvement – adjuvant endocrine therapy, chemotherapy with trastuzumab.
Slide 33-

Hormone Receptor Negative, HER2 Positive Breast Cancer 0.5 cm or less tumor size – No chemo. 0.6 to 1 cm – Consider chemo with trastuzumab. > 1 cm tumor size and/or lymph node involvement – chemotherapy with trastuzumab. HORMONAL THERAPY NOT USEFUL.
Slide 34-

Hormone Receptor Positive, HER2 Positive Breast Cancer 0.5 cm or less tumor size – Adjuvant endocrine therapy 0.6 to 1 cm – Adjuvant endocrine +/- chemo with trastuzumab. > 1 cm tumor size and/or lymph node involvement – adjuvant endocrine therapy, chemotherapy with trastuzumab.
Slide 35-

Hormone Receptor Positive HER2 Negative Breast Cancer - Tumor size Tumor size < 0.5 Cm and No LN involvement – Adjuvant endocrine therapy. No chemotherapy T > 0.5 Cm and No LN involvement - adjuvant endocrine therapy +/- ?? Chemo.
Slide 36-

Hormone Receptor Positive HER2 Negative Breast Cancer Nodal involvement > 2mm focus – adjuvant endocrine therapy + chemotherapy 1 to 3 Lymph nodes or >3 nodes involved – does every one need chemo?
Slide 37-

Topics Role of genetic/familial high risk assessment Role of specific markers on breast tissue in decision making of treatment. For some patients, more(=chemotherapy) is not better. - Role of genetic profiling of the tumor in decision making.
Slide 38-

How Do We Assess Risk in Breast Cancer Patients? Classic Pathological Criteria Genetic Profiling of Tumor New tools in the Genomic Era… Age Tumor Size Lymph Node Status ER/PR HER2 Tumor Grade AdjuvantOnline! Computer-based model
Slide 39-

Adjuvant Treatment for Early Stage Breast Cancer Today
Slide 40-

Hormonal Therapy If 100 women with ER+, N- disease are treated with hormonal therapy how many will recur within 10 years? Based on the Landmark NSABP B-14 Study using Tamoxifen
Slide 41-

Chemotherapy and Hormonal Therapy If all 100 women with ER+, N- disease are treated with chemotherapy and hormonal therapy, how many will benefit from the addition of chemotherapy? Based on the Landmark NSABP B-20 Study using Tamoxifen + Chemotherapy
Slide 42-

Outcomes of Adjuvant Chemotherapy in Breast Cancer Walgren et al. JCO 2005;23:7342-7349
Slide 43-

How Do We Assess Risk in Breast Cancer Patients? Classic Pathological Criteria Genetic Profiling of Tumor New tools in the Genomic Era… Age Tumor Size Lymph Node Status ER/PR HER2 Tumor Grade AdjuvantOnline! Computer-based model
Slide 44-

Patient A
Slide 45-

Patient B
Slide 46-

Patient C
Slide 47-

With Genomic Tools We Can Now Analyze Cancer at the Molecular Level
Slide 48-

Oncotype DX®: A Genomic Assay
Slide 49-

Oncotype DX® 21-Gene Recurrence Score® (RS) Assay PROLIFERATION Ki-67 STK15 Survivin Cyclin B1 MYBL2 ESTROGEN ER PR Bcl2 SCUBE2 INVASION Stromelysin 3 Cathepsin L2 HER2 GRB7 HER2 BAG1 GSTM1 REFERENCE Beta-actin GAPDH RPLPO GUS TFRC CD68 16 Cancer and 5 Reference Genes From 3 Studies Paik et al. N Engl J Med. 2004;351: 2817-2826
Slide 50-

Oncotype DX® 21-Gene Recurrence Score® (RS) Assay Calculation of the Recurrence Score Result Paik et al. N Engl J Med. 2004;351: 2817-2826
Slide 51-

The Oncotype DX® Assay mostly used for N-, ER+ Breast Cancer Patients
Slide 52-

Patient A
Slide 53-

Patient A Patient was identified as low risk by Oncotype DX® with a Recurrence Score ® result of 4 Patient received hormonal therapy since she was in a group in which chemotherapy does not provide benefit
Slide 54-

Patient B
Slide 55-

Patient was identified as high risk by Oncotype DX® with a Recurrence Score® result of 34 The Recurrence Score helped convince the patient on the likely benefits of taking chemotherapy given the biology of her disease Patient received chemotherapy and hormonal therapy Patient B
Slide 56-

Patient C
Slide 57-

Patient was identified as intermediate risk by Oncotype DX® with a Recurrence Score® result of 25 Is there benefit from chemotherapy for this patient? The TAILORx trial evaluates the utility of chemotherapy in the mid-range risk group Patient C
Slide 58-

Outcomes of Adjuvant Chemotherapy in Breast Cancer Walgren et al. JCO 2005;23:7342-7349
Slide 59-

Tamoxifen Chemotherapy Anth, Taxane, Platimun Women with HR+ breast Cancer Aromatase Inhibitor Biologic agents Her2, EGFR, VEGF, Parp The Promise of Personalized Medicine in Breast Cancer
Slide 60-

The Molecular Portrait Hypothesis You can recognize the Mona Lisa by her smile and her nose and her eyes and even her hands – if you are really good, but not the sky or the trees
Slide 61-

Thank you. Questions?